Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Valion Bio, formerly Tivic Health Systems, reports developments tied to its transformation into a biopharmaceutical company focused on innate-immune therapeutics. Company news centers on Entolimod™, a TLR5 agonist lead candidate for acute radiation syndrome, related gastrointestinal radiation-injury work, broader oncology supportive-care applications, and pipeline depth from Entolasta™.
Updates also cover the company’s wholly owned Velocity Bioworks subsidiary, a full-service CDMO providing analytical testing, process development, and cellular and biologic therapy manufacturing services. Recurring announcements include government and public-health preparedness engagement, nonclinical study agreements, financial results, corporate presentations, leadership changes, and the completed name and ticker change from TIVC to VBIO.
Tivic Health Systems, Inc. (NASDAQ: TIVC) has received significant recognition as CEO Jennifer Ernst was awarded Inc’s 2021 Female Founders 100 Award. Additionally, the company was listed in Fast Company’s inaugural Next Big Things in Tech 2021 for its FDA-cleared product, ClearUP® Sinus Pain Relief. This innovative device aims to alleviate nasal and sinus inflammation symptoms, marking a key milestone in the bioelectronic medicine sector. Ernst expressed pride in the team’s accomplishments and their mission to enhance healthcare delivery.
Tivic Health Systems, a commercial-phase bioelectronic medicine company, will present at the Sidoti Micro Cap Conference virtually on December 8, 2021, at 3:15 pm ET. CEO Jennifer Ernst will discuss bioelectronic medicine's growth and hold one-on-one investor meetings. Registration for the conference is mandatory, and more details can be found on Sidoti's website. Tivic Health is committed to advancing non-invasive health solutions to enhance wellness and improve lives.
Tivic Health Systems, Inc. (TIVC) announced the closing of its initial public offering, selling 3 million shares at $5.00 each, raising $15 million in gross proceeds. The offering includes a 45-day option for underwriters to purchase an additional 450,000 shares. The proceeds will be used to expand sales of its ClearUP® Sinus Relief device, enhance marketing efforts, and support the launch of ClearUP Gen 2. The company also aims to further clinical research and product development. ThinkEquity acted as the sole book-running manager for the offering.